Ryan Haumschild, PharmD, MS, MBA, CPEL

Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.

Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.

Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.

Panelists discuss how innovative neurokinin-targeted therapies for vasomotor symptoms can reshape menopause management and address unmet needs and improving patient outcomes while highlighting the importance of equity in treatment access.

Experts discuss future directions of BTK inhibitors.

A panel of specialists discuss patient access advocacy for BTK inhibitors.